TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35041627
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen plus 500 mL PEG after SBCE ingestion (prep 2)
Study: 35041627
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen plus 2 L PEG plus 500 mL PEG after SBCE ingestion (prep 3)
Study: 33373286
Drug: Spray-inoculated with
Normalized name: dimethicone / zinc oxide Topical Spray [Rash Relief with Zinc Oxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray-inoculated with a suspension of conidia (1×10^5 spores/ml) for 7 days
Study: 36152778
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol (target level: 0.05 g%)
Study: 33383230
Drug: Mind (tablet‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind (tablet‐based cognitive training)
Study: 34348526
Drug: Drospirenone 4
Normalized name: drospirenone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 4 mg
Study: 32664877
Drug: Cinepazide maleate
Normalized name: cinepazide maleate
DrugBank: Cinepazide (DB12123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinepazide maleate injection (320 mg, intravenous infusion, once daily for 14 days)
Study: 33468249
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (GS; 1500 mg) and bovine chondroitin sulfate (CS; 1200 mg)
Study: 34889733
Drug: Topiroxostat 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 200 mg
Study: 34889733
Drug: Topiroxostat 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 80 mg
Study: 34889733
Drug: Allopurinol 200
Normalized name: allopurinol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 200 mg
Study: 34889733
Drug: Topiroxostat 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 120 mg
Study: 34889733
Drug: Topiroxostat 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 160 mg
Study: 34889733
Drug: Topiroxostat 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 40 mg
Study: 34397820
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration simethicone solution (S2‐)
Study: 34397820
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration simethicone solution (S1‐)
Study: 32941395
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) Cmin of 4-7 ng/mL
Study: 32941395
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) Cmin of 4-7 ng/mL after propensity score matching
Study: 32941395
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) Cmin of 7-10 ng/mL
Study: 32941395
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) Cmin of >10 ng/mL
Study: 34191033
Drug: NAD+-precursor supplementation
Normalized name: nicotinamide adenine dinucleotide (NAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAD+-precursor supplementation (207.5 mg niacin equivalents/day) for 32 days
Study: 32435772
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with chitosan nanoparticles (Csnp) solution under ultrasonic agitation for 60 s and immersed in EDC crosslinker for 24 h
Study: 32522244
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg orally two times per day for 10 days (n = 140)
Study: 32522244
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G 2.4 million units intramuscularly based on the stage of syphilis infection (n = 70)
Study: 32977975
Drug: As-needed acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed acetaminophen + codeine
Study: 32977975
Drug: Scheduled acetaminophen/as-needed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled acetaminophen/as-needed tramadol
Study: 35784564
Drug: MMI monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMI monotherapy
Study: 32827483
Drug: Intravenous cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatin
Study: 35123569
Drug: Internet-supported mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-supported mindfulness-based cognitive therapy (MBCT) for 8 weeks with weekly group sessions via videoconference, asynchronous homework, an online retreat after the fifth week, and 4 monthly booster sessions after completion of the 8-week programme.
Study: 37038176
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control treatment
Study: 35868146
Drug: Once-weekly LAGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly LAGH (0.7 mg/kg/week)
Study: 35868146
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH (0.37 mg/kg/week)
Study: 32645310
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of mitomycin C (MMC)
Study: 34462956
Drug: Synbiotic capsules
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic capsules
Study: 33108247
Drug: MARS compared
Approvals — FDA: no, EMA: no, PMDA: no
Description: MARS compared with caregiver-reported medication adherence
Study: 33108247
Drug: MARS compared
Approvals — FDA: no, EMA: no, PMDA: no
Description: MARS compared with Asthma Medication Ratio (AMR), asthma control, and caregiver perception of asthma control
Study: 35320964
Drug: Intrathecal 3
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal 3 mg hyperbaric bupivacaine 0.5% plus 20 microgram fentanyl and intravenous fentanyl at 1μg.kg(‐1).h(‐1)
Study: 35320964
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl at 1μg.kg(‐1).h(‐1) and laparoscopic port site infiltration with 0.5% bupivacaine
Study: 35929466
Drug: Fluoxetine intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine intervention
Study: 35929466
Drug: No fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fluoxetine intervention (Control)
Study: 36380693
Drug: Tofacitinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (10 mg/bid for 2 weeks)
Study: 32485656
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg MAS-ER
Study: 32485656
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg MAS-ER
Study: 32208351
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (3 cycles of epirubicin, cisplatin or oxaliplatin and capecitabine) followed by surgery and either postoperative chemotherapy or chemoradiotherapy (45Gy + cisplatin + capecitabine)
Study: 34480630
Drug: Cannabidiol 600
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol 600 mg
Study: 35447145
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% imiquimod cream
Study: 35357290
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion therapy
Study: 33664007
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg per day)
Study: 35905339
Drug: Previous L‐independent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous L‐independent approaches (e.g., qDRIFT)
Study: 32666349
Drug: Probiotic gel
Normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic gel and lozenges (n=20)
Study: 36191882
Drug: Adebrelimab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab (20 mg/kg on day 1), nab-paclitaxel (100 mg/m2 on days 1, 8, and 15), and carboplatin (AUC 5 mg/mL per min on day 1) as neoadjuvant treatment followed by 16 cycles of adebrelimab (20 mg/kg on day 1 every 3 weeks) as adjuvant treatment.
Study: 33951024
Drug: Indwelling analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indwelling analgesic catheter (IC)
Study: 33951024
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose liposomal bupivacaine (LB)
Study: 32648394
Drug: Waiting-list group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list group (no intervention except ibuprofen when necessary).
Study: 39047240
Drug: Chemotherapy-only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-only
Study: 35301859
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg glibenclamide
Study: 32251303
Drug: Dietary restriction
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary restriction (DR) - formula diet containing 60% of daily energy requirement during the 4-day interval before PCI
Study: 32251303
Drug: Dietary restriction
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary restriction (DR) - formula diet containing 60% of daily energy requirement
Study: 34511586
Drug: IV OPC‐61815
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV OPC‐61815 16 mg
Study: 34511586
Drug: Oral tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tolvaptan 15 mg
Study: 32001003
Drug: Naturalistic controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturalistic controls (treatment as usual)
Study: 33449534
Drug: Amantadine sulfate
Normalized name: amantadine sulfate
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine sulfate (400 mg/day intravenously for 4 days, followed by oral administration at 400 mg/day for 6 days)
Study: 33449534
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy according to the order of the Ministry of Health of the Russian Federation No. 928n
Study: 34967830
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control (riboflavin ophthalmic solution)
Study: 32369007
Drug: Computerised speech
Normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised speech and language therapy
Study: 34399136
Drug: Video directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video directly observed therapy (DOT) using a HIPAA-compliant smartphone application
Study: 33528004
Drug: Tailored Therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored Therapeutic Exercise and Recovery Strategies (ATOPE) program, performed before treatment, with 12 to 18 sessions of tailored, high‐intensity exercise and post‐exercise recovery strategies.
Study: 33612068
Drug: PSA-test; if
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA-test; if PSA ≥ 3 ng/mL, then MRI and systematic biopsy, plus targeted biopsy to suspicious lesions as per PI-RADSv2 3–5
Study: 33612068
Drug: PSA-test; if
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA-test; if PSA ≥ 3 ng/mL, then MRI, and targeted biopsy only if PI-RADSv2 3–5
Study: 33612068
Drug: Identical to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical to Arm 2, except lower PSA-cut-off ≥1.8 ng/mL
Study: 32307933
Drug: LIPUS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIPUS therapy combined with Twin-Block appliance
Study: 32307933
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (observational, no treatment)
Study: 34028967
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg daily plus 177Lu-PSMA-617 7.5 GBq on Days 15 and 57 (up to four doses total)
Study: 34028967
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg daily alone
Study: 32618249
Drug: SoC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoC plus focal mass drug administration (fMDA)
Study: 32618249
Drug: SoC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoC plus mass drug administration (MDA)
Study: 32315461
Drug: Pharmacist-conducted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-conducted medication review
Study: 35545875
Drug: Topical product
Normalized name: Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical product (Group C) - cream formulation containing hydroxypinacolone/retinyl palmitate, Iris Florentina root extract, and a complex of three oligopeptides applied twice a day.
Study: 35545875
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Group C + O) - topical product plus prebiotic food supplement (FOS&GOS, zinc, lactoferrin, niacinamide).
Study: 34692934
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy group (CT) with conventional rehabilitation for 6 weeks
Study: 33332873
Drug: Open biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open biological mesh
Study: 33332873
Drug: Laparoscopic biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic biological mesh
Study: 33332873
Drug: Biological mesh
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological mesh (overall)
Study: 35531961
Drug: Newborn Behavioral
Normalized name: Vital E- Newborn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newborn Behavioral Observations (NBO) plus treatment as usual (TAU)
Study: 35421875
Drug: Regular western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular western medicine (Control)
Study: 616122612
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg t.i.d for 1 month
Study: 35882451
Drug: Education on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education on exercise and COVID‐19 recovery trajectory, physical activity and vitals monitoring, and weekly check‐ins with study staff (n=15)
Study: 35320216
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality exercises with routine physical therapy
Study: 36344629
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of mirabegron and solifenacin
Study: 36344629
Drug: Solifenacin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin therapy (Control)
Study: 35849476
Drug: relugolix-combination therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: relugolix-combination therapy (relugolix-CT)
Study: 33038408
Drug: Autonomic regulation
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic regulation therapy (ART) utilizing cervical vagus nerve stimulation (VNS) for 6 months post-titration
Study: 36934987
Drug: Autonomic regulation
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic regulation therapy (ART) utilizing cervical vagus nerve stimulation (VNS)
Study: 32990858
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (placebo) injections
Study: 33795299
Drug: Biological mesh
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological mesh repair
Study: 33210178
Drug: Apremilast (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast (in vivo administration)
Study: 33210178
Drug: PsO-MSCs T0
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PsO-MSCs T0 (before treatment)
Study: 33210178
Drug: PsO-MSCs T12
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PsO-MSCs T12 (after treatment)
Study: 33686446
Drug: Fractional laser-assisted
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional laser-assisted topical corticosteroid delivery
Study: 33686446
Drug: Fractional laser
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional laser monotherapy
Study: 33691056
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (1 mL)
Study: 33691056
Drug: Granisetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (1 mg in 1 mL)
Study: 32306525
Drug: HSF™-based skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSF™-based skin care formulation
Study: 38159652
Drug: Anticonvulsants
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsants
Study: 32545143
Drug: Moringa leaf
Normalized name: Moringa oleifera leaf oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa leaf extract and iron capsules
Study: 32545143
Drug: Iron capsules
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron capsules
Study: 39506661
Drug: Treatment-as-usual group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual group
Study: 33997885
Drug: Dexamethasone suppression
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone suppression test (DST) with method-specific cortisol cutoff of 2.4 µg/dL
Study: 33997885
Drug: Dexamethasone <1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone <1.8 ng/mL in AI-ACS samples
Study: 35078116
Drug: Perampanel (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (maximum dose: 12 mg/day)
Study: 35482347
Drug: Experimental agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental agent (cancer drug)
Study: 38620092
Drug: Targeted drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted drugs
Study: 35482347
Drug: Immunotherapy drugs
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy drugs
Study: 35482347
Drug: Non-immunotherapy-targeted drugs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-immunotherapy-targeted drugs
Study: 33325793
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone (IVD) implant
Study: 33325793
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IVD implant)
Study: 33091102
Drug: Monthly audits
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly audits of all ADC pockets
Study: 33091102
Drug: Monthly audits
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly audits of matrix (open pocket) drawers only
Study: 33091102
Drug: Monthly audits
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly audits of unassigned pockets only
Study: 36459910
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PTB) applied at pain points (G2) with a dose of 4 J and 6 J.
Study: 36459910
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PTB) applied at pre-established points (G1) with a dose of 4 J and 6 J.
Study: 33538902
Drug: Increased blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased blood pressure to 150 mmHg for 5 min using norepinephrine pump (0.05 μg/kg/min initial dose) after specimen extraction during ESD
Study: 34312043
Drug: SCT+HE (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT+HE (Standard Conservative Therapy plus Home Exercise)
Study: 34312043
Drug: SCT (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT (Standard Conservative Therapy)
Study: 32603281
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive surgical therapies (MISTs)
Study: 32603281
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (drugs)
Study: 35189848
Drug: Group self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group self-management support (10 weekly 2.5-hour group web-based sessions with 10-15 patients and two trained facilitators)
Study: 36470757
Drug: Social media-based
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social media-based drama therapy
Study: 36470757
Drug: Social media-based
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social media-based art therapy
Study: 36470757
Drug: Social media-based
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social media-based music therapy
Study: 35393218
Drug: Full 90-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full 90-minute HBOT dose in a pressurized chamber with 100% oxygen at 2.0 ATA